Cooley M&A

JANUARY 25, 2023

Amid depressed valuations, biotechnology companies also saw an increasing number of demands from activist investors that in certain cases led to more deal activity. For example, the sale of Horizon Therapeutics to Amgen for approximately $28 billion was the third-largest all-cash transaction in the pharmaceutical sector in history.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

OCTOBER 29, 2018

M&A practitioners have long advised boards of directors that the Delaware courts have never found that the events or circumstances in a particular transaction met the contractual standard of having a material adverse effect (or MAE) as defined in a merger or acquisition agreement. The Merger Agreement. Fresenius Kabi AG , C.A.

Mergers and Acquisitions 52

Mergers and Acquisitions Mergers Business Pharmaceutical 52

Cooley M&A

JANUARY 22, 2021

The second half of the year witnessed a rebound spurred by several multibillion-dollar deals, including Gilead’s acquisition of Immunomedics for nearly $21 billion and AstraZeneca’s proposed acquisition of Alexion Pharmaceuticals for $39 billion. Life Sciences Enters the SPAC Party, But Will Reverse Merger Suitors Join In?

M&A 40

M&A Mergers and Acquisitions Collaboration Mergers 40

Cooley M&A

FEBRUARY 8, 2018

One familiar technique used by sophisticated tech buyers is a holdback structure that subjects a portion of key employees’ merger consideration to revesting. See ABA Private Target Mergers & Acquisitions Deal Point Study for 2016-2017. The typical revesting period for these arrangements is 24 to 36 months.

M&A 52

M&A Mergers and Acquisitions Mergers Negotiation 52

OfficeHours

JANUARY 26, 2024

That hadn’t previously been the case since 2009 and highlights how falling valuations and tighter credit markets have forced firms to keep assets for longer than typical five-year investment cycles. Some dealmakers claim the impact of elections on mergers and acquisitions is minimal. billion ($5.7

Private Equity 130

Private Equity Equities Mergers and Acquisitions Investors 130

Cooley M&A

JANUARY 20, 2022

1] Major all-cash acquisitions have followed, such as Arena Pharmaceutical’s agreement to sell to Pfizer for $6.7 Midsize pharmaceutical buyers pursuing opportunistic acquisition strategies, with robust capital markets and high valuations having limited the pool of attractive assets available in recent years.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40

Mergers and Inquisitions

NOVEMBER 1, 2023

Mispriced Companies and Assets – Some mature healthcare firms trade at low valuation multiples , often because the market misunderstands their contracts, revenue, or track record. Areas like healthcare services and medical devices are fairly generalist and follow standard accounting and valuation. For example, in the U.S.,

Private Equity 59

Private Equity Healthcare Equities Middle Market 59

InvestmentBank.com

MAY 18, 2021

The healthcare industry is formed of numerous subsectors including pharmaceutical services, diagnostics, medical technologies, and managed healthcare. Payor services and pharmaceutical services have generated the most return throughout 2016 and in 1Q 2017. The pharmaceutical industry is valued highly given the performance of buyouts.

Healthcare 40

Healthcare M&A Valuation Hospitality 40